Sunho Biologics Inc (HKSE:02898) Share Price

Company Profile

Business description
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
Contact
No. 198 Peninsula Middle Road, Dipu Street
Room 302, Building 3
Anji County
Zhejiang Province
Huzhou
CHN
http://www.sunho-bio.com.cn
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
130

Recommended

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 30 July 2025

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Shaun Ler | 30 July 2025

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.

Malik Ahmed Khan, CFA | 30 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,995.80	19.60	-0.22%
CAC 40	7,861.96	4.60	0.06%
DAX 40	24,262.22	44.85	0.19%
Dow JONES (US)	44,461.28	171.71	-0.38%
FTSE 100	9,136.94	0.62	0.01%
HKSE	24,799.91	377.02	-1.50%
NASDAQ	21,129.67	31.38	0.15%
Nikkei 225	41,102.12	447.42	1.10%
NZX 50 Index	12,823.74	32.23	-0.25%
S&P 500	6,362.90	7.96	-0.12%
S&P/ASX 200	8,740.20	16.20	-0.19%
SSE Composite Index	3,580.98	34.73	-0.96%